Skip to main content
. Author manuscript; available in PMC: 2021 Aug 11.
Published in final edited form as: J Allergy Clin Immunol. 2021 Jan 23;148(2):533–549. doi: 10.1016/j.jaci.2021.01.008

Figure 4. Peripheral blood traits and HDM-PARC phenotypes.

Figure 4.

(A) Proportion of controls (ctrl.) and HDM-PARC participants stratified by phenotypes (resilient [R], adaptive [A], maladaptive [M]) with the indicated peripheral blood trait strata at baseline [pre-exposure (Exp) 1] and who developed symptoms of airway hyperresponsiveness (AHR) in ACC-I. P, determined by Fisher’s exact test comparing R vs. A+M, or M vs. R+A. Cutoff for ILC2-ST2+ cells evaluated as a categorical variable: ILC2-ST2hi: ≥ 11.47 log2-cells/μL (B) Trajectories (cell counts/1×106 PBMCs) of (left) CD158b+CD56+CD3+ and (right) CD159a+CD56+CD3+ cells at pre- and post-Exp 1 and 4 in HDM-PARC participants stratified by CD8hi and CD8lo, and HDM-PARC phenotypes (R, A, M). P, for difference across all 4-time points comparing CD8hi vs. CD8lo or M vs. A+R. (C-F) Trajectories of percent (log2-transformed) abundance within PBMCs of (C) CD8+ among CD3+ T-cells, (D) CD158b+ among CD8+MAITNeg T-cells, (E) mature NK cells, and (F) MAIT+ among CD4+ T cells at pre- and post-Exp 1 and 4 in HDM-PARC phenotypes (R, A, M). (C-F) P, for the difference across all 4 time points comparing M vs. A+R. FDR, false discovery rate; Hi, higher; Lo, lower. Methods for deriving significance values in Supplement.